Lymphoma, Non-Hodgkin
Showing 26 - 50 of >10,000
Non Hodgkin Lymphoma Trial in Philadelphia (Pembrolizumab)
Recruiting
- Non Hodgkin Lymphoma
-
Philadelphia, PennsylvaniaAbamson Cancer Center of the University of Pennsylvania
Jan 9, 2023
Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)
Recruiting
- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
- dualCAR-NK19/70 cell
-
Shanghai, Shanghai, ChinaShanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023
Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)
Not yet recruiting
- Advanced Solid Tumor
- Refractory Non-Hodgkin Lymphoma
- (no location specified)
May 28, 2023
Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)
Recruiting
- Lymphoma, Non-Hodgkin
- Diffuse Large B Cell Lymphoma
- CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
-
Tianjin, Tianjin, ChinaTianjin Cancer Hospital
Nov 19, 2023
Lymphoma, Non-Hodgkin, Myeloma Multiple Trial (Connected scale "Body Comp Pro" from Withings)
Not yet recruiting
- Lymphoma, Non-Hodgkin
- Myeloma Multiple
- Connected scale "Body Comp Pro" from Withings
- (no location specified)
Nov 9, 2023
CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)
Recruiting
- CD20-positive B-cell Non-Hodgkin's Lymphoma
-
Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023
Living Conditions After Non-Hodgkin's Lymphoma in France
Not yet recruiting
- Non-hodgkin's Lymphoma
- Data collection
- Questionnaires
-
Dijon, FranceChu Dijon Bourgogne
Oct 13, 2022
Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)
Not yet recruiting
- Relapsed Non-Hodgkin Lymphoma
- +6 more
- (no location specified)
Apr 12, 2023
DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,
Not yet recruiting
- DLBCL - Diffuse Large B Cell Lymphoma
- +6 more
- Bridging radiation therapy
- +2 more
- (no location specified)
Jan 4, 2023
Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma Trial in San Antonio (WTX-330)
Recruiting
- Advanced or Metastatic Solid Tumors
- Non-Hodgkin Lymphoma
-
San Antonio, TexasNEXT Oncology
Jan 6, 2023
Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive
Active, not recruiting
- Aggressive B-Cell Non-Hodgkin Lymphoma
- fractionated first dose rituximab
-
Geneva, SwitzerlandUniversity Hospital Geneva
Apr 21, 2023
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)
Enrolling by invitation
- Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Obinutuzumab
- +6 more
-
Suzhou, Jiangsu, Chinathe First Affiliated Hospital of Soochow University
Mar 22, 2023
Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)
Not yet recruiting
- Relapsed or Refractory Non-Hodgkin's Lymphoma
-
Beijing, China
- +3 more
Jul 20, 2023
Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)
Not yet recruiting
- Non-Hodgkin's Lymphoma, Relapsed
- +2 more
- (no location specified)
Dec 6, 2022
Immunogenicity of COVID-19 Vaccinations in Autologous HSCT
Not yet recruiting
- COVID-19
- +2 more
-
Cologne, NRW, GermanyUniversity Hospital of Cologne
Oct 27, 2022
B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)
Not yet recruiting
- B-cell Non Hodgkin Lymphoma
- CB dualCAR-NK19/70
-
Hanzhou, Zhejiang, China2nd Affiliated Hospital, School of Medicine, Zhejiang University
Dec 25, 2022
CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)
Terminated
- CD20-positive Non-Hodgkin Lymphoma
- Rituximab + MG4101
-
Seoul, Korea, Republic ofSeoul National University Hospital
Oct 24, 2022
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Duarte, Hackensack, Houston (SIRPant-M, External-beam
Not yet recruiting
- Refractory Non-Hodgkin Lymphoma
- Relapsed Non-Hodgkin Lymphoma
- SIRPant-M
- External-beam radiotherapy (XRT)
-
Duarte, California
- +2 more
Jul 21, 2023
Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,
Recruiting
- Advanced Solid Tumors
- +2 more
- GIC-102 (Allogeneic NK cells)
-
Gyeonggi-do, Korea, Republic of
- +3 more
May 18, 2023
Non-Hodgkin Lymphoma, Large B-cell Lymphoma Trial in Palo Alto (Axicabtagene Ciloleucel)
Not yet recruiting
- Non-Hodgkin Lymphoma
- Large B-cell Lymphoma
- Axicabtagene Ciloleucel
-
Palo Alto, CaliforniaStanford University
Mar 20, 2023
B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)
Recruiting
- B-cell Non-Hodgkin Lymphoma (B-NHL)
- UCART20x22
- CLLS52
-
Austin, TexasSarah Cannon - St. David South Austin Medical Center
Dec 8, 2022
Solid Tumor, Non-Hodgkin Lymphoma Trial in Guangzhou, Shanghai (ADG106)
Active, not recruiting
- Solid Tumor
- Non-Hodgkin Lymphoma
-
Guangzhou, Guangdong, China
- +1 more
Oct 15, 2022
CB-Long-Term Safety Study (CB-LTSS)
Enrolling by invitation
- Lymphoma, Non-Hodgkin
- +7 more
- Allogeneic CAR-T therapy
-
Irvine, California
- +3 more
Nov 18, 2022